DCxBio is a startup based in Canada.
DCxBio develops next-generation precision multi-modal antibody drug conjugates using an integrated CRISPR, bioinformatics, and machine learning platform to target cancer at its cellular roots by identifying lesion-specific targets for improved therapeutic responses.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.